Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/novartis-ag">Novartis </a>is strategically transforming into a 'pure-play' innovative medicines company, focusing on high-margin therapeutic areas and divesting non-core assets like its Sandoz generics division.</li>
  <li>The company faces a significant headwind in 2026 from its largest patent expiry event in history, with generic competition for key drugs like Entresto, Promacta, and Tasigna expected to impact revenues by approximately $4 billion.</li>
  <li>Future growth is contingent on the successful commercialization of its robust pipeline and key in-market brands such as Kisqali, Kesimpta, Pluvicto, and Scemblix, which are expected to offset revenue losses from patent cliffs and drive a projected 5-6% sales CAGR from 2025-2030.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Novartis is strategically transforming into a 'pure-play' innovative medicines company, focusing on high-margin therapeutic areas and divesting non-core assets like its Sandoz generics division.
  The company faces a significant headwind in 2026 from its largest patent expiry event in history, with generic competition for key drugs like Entresto, Promacta, and Tasigna expected to impact revenues by approximately $4 billion.
  Future growth is contingent on the successful commercialization of its robust pipeline and key in-market brands such as Kisqali, Kesimpta, Pluvicto, and Scemblix, which are expected to offset revenue losses from patent cliffs and drive a projected 5-6% sales CAGR from 2025-2030.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Switzerland

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novartis (NOVN SE)

Primer: Novartis (NOVN SE) - Apr 2026

Novartis is strategically transforming into a 'pure-play' innovative medicines company, focusing on high-margin therapeutic areas and divesting...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)